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Abstract
Previously, arsenic trioxide showed impressive regression rates of acute promyelocytic leukemia. Here, we investigated
molecular determinants of sensitivity and resistance of cell lines of different tumor types towards arsenic trioxide. Arsenic
trioxide was the most cytotoxic compound among 8 arsenicals investigated in the NCI cell line panel. We correlated
transcriptome-wide microarray-based mRNA expression to the IC50 values for arsenic trioxide by bioinformatic approaches
(COMPARE and hierarchical cluster analyses, Ingenuity signaling pathway analysis). Among the identified pathways were
signaling routes for p53, integrin-linked kinase, and actin cytoskeleton. Genes from these pathways significantly predicted
cellular response to arsenic trioxide. Then, we analyzed whether classical drug resistance factors may also play a role for
arsenic trioxide. Cell lines transfected with cDNAs for catalase, thioredoxin, or the anti-apoptotic bcl-2 gene were more
resistant to arsenic trioxide than mock vector transfected cells. Multidrug-resistant cells overexpressing the MDR1, MRP1 or
BCRP genes were not cross-resistant to arsenic trioxide. Our approach revealed that response of tumor cells towards arsenic
trioxide is multi-factorial.
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Introduction
Arsenic is a natural semimetal in soil, water and air. It exists as
red arsenic (As2S2), yellow arsenic (As2S3), white arsenic (As2O3,
arsenic trioxide), phenylarsine oxide (C6H5AsO), and as salts of
sodium, potassium and calcium [1]. Since ancient times arsenic was
used for medical purposes [2]. Arsenic was appreciated as Fowler’s
Solution for many diseases in the 18
th and 19
th century, i.e., syphilis,
cancer, ulcers, etc. [3]. In the 20
th century, Paul Ehrlich, the
founder of modern chemotherapy, found the arsenical salvarsan,
which was the standard therapy against syphilis for decades [4]. On
the other side, arsenic compounds can be poisonous [5]. The
revival of arsenic in modern medicine was initiated by Chinese
scientists showing dramatic regression rates of acute promyelocytic
leukemia by arsenic trioxide [6]. These findings were subsequently
corroborated in clinical studies in the USA [7].
Various molecular determinants of the biological effect of
arsenic trioxide have been elucidated. It promotes the degradation
of the oncogenic fusion protein of the PML and retinoic acid
receptor a (RARa) genes which arises from t(15;17) translocation
in acute promyelocytic leukemia, resulting in induction of cellular
differentiation [7,8]. Apoptosis is selectively induced in malignant
cells through enhancement of reactive oxygen species and
activation of caspases [9–12]. Cells can arrest in the G1 or G2/
M phases of the cell cycle after treatment with arsenic trioxide
[12]. Tumor angiogenesis is targeted by arsenic trioxide through
inhibition of vascular epithelial growth factor production [13].
While focusing on mono-specific drugs without adverse effects
on normal tissues, it turned out that drug resistance frequently
occurs. Subpopulations of cancer cells with specific point
mutations in target proteins can survive attacks of mono-specific
drugs due to reduced binding affinity to these drugs. They
overgrow the entire tumor population resulting in drug-resistant
phenotypes, as in the case of GleevecH resistance [14]. Therefore,
it has recently been proposed that multi-target attacking drugs
maybe superior by avoiding development of resistance to single
mono-specific drugs. The development of multi-kinase inhibitors
represents an example for this novel treatment concept.
The aim of the current study was to investigate sensitivity and
resistance of tumor cells towards arsenic trioxide. For this reason,
we first analyzed transcriptome-wide microarray-based mRNA
expression by bioinformatic approaches (COMPARE and hierar-
chical cluster analyses, Ingenuity signaling pathway analysis) to
identify novel molecular determinants for response of the cell line
panel of the National Cancer Institute (NCI), USA, towards
arsenic trioxide [15].
A second aim was to analyze whether classical determinants of
resistance towards established anti-cancer drugs may also play a
role in arsenic trioxide resistance. To this end, anti-oxidative stress
response genes as well as multidrug resistance transporters have
been tested for their influence on arsenic trioxide resistance. A
major obstacle of cancer therapy is the development of cross-
resistance and even worse multidrug resistance [16–17]. The role
of the drug transporters P-glycoprotein (Pgp, MDR1, ABCB1) and
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10multidrug resistance related protein 1 (MRP1, ABCC1) has been
discussed with contradictory results [18–21] and it is unclear
whether or not arsenic trioxide is transported by these two
multidrug resistance pumps. Therefore, we have readdressed this
question. Furthermore, we analyzed the breast cancer resistance
protein (BCRP, ABCG2) whose relevance for resistance to arsenic
is unknown as yet.
Furthermore, it has been claimed that arsenic trioxide generates
reactive oxygen species (ROS) [22–24] leading to apoptosis. The
role of ROS-detoxifying enzymes for arsenic trioxide has been
investigated. Again, conflicting data have been reported [25–27].
Since most of these studies only measured enzymatic activities, we
used cell lines transfected with cDNAs for catalase or thioredoxin
to clarify whether or not these genes confer resistance to arsenic
trioxide.
Materials and Methods
Cell Lines
The panel of 60 human tumor cell lines of the Developmental
Therapeutics Program of the NCI, USA, consisted of leukemia
(CCRF-CEM, HL-60, K-562, MOLT-4, RPMI-8226, SR),
melanoma (LOX-IMVI, MALME-3M, M14, SK-MEL2, SK-
MEL28, SK-MEL-5, UACC-257, UACC-62), non-small cell lung
cancer (A549, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23,
NCI-H322M, NCI-460, NCI-H522), colon cancer (COLO205,
HCC-2998, HCT-116, HCT-15, HT29, KM12, SW-620), renal
cancer (786-0, A498, ACHN, CAKI-1, RXF-393, SN12C, TK-
10, UO-31), ovarian cancer (IGROV1, OVCAR-3, OVCAR-4,
OVCAR-5, OVCAR-8, SK-OV-3) cell lines, cell lines of tumors
of the central nervous system (SF-268, SF-295, SF-539, SNB-19,
SNB-75, U251), prostate carcinoma (PC-2, DU-145), and breast
cancer (MCF-7, NCI/ADR-Res, MDA-MB-231, Hs578T, MDA-
MB-435, MDA-N, BT-549, T-47D). Their origin and processing
have been previously described [28].
Multidrug-Resistant Tumor Cell Lines: Leukemic CCRF-CEM
cells were maintained in RPMI 1640 medium (Invitrogen,
Eggenstein, Germany) supplemented with 10% fetal calf serum
in a humidified 5% CO2 atmosphere at 37uC. Cells were passaged
twice weekly. All experiments were performed with cells in the
logarithmic growth phase. P-glycoprotein/multidrug resistance
gene 1 (MDR1)-expressing CEM/ADR5000 cells were maintained
in 5000 ng/ml doxorubicin. The establishment of the resistant
subline has been described [29].
The multidrug-resistance gene 1 (MRP1)-expressing HL-60/
AR subline was continuously treated with 100 nM daunorubicin.
The establishment of this cell line has been reported (Bru ¨gger
et al., 1999) [30]. Sensitive and resistant cells were kindly provided
by Dr. J. Beck (Department of Pediatrics, University of Greifswald,
Greifswald, Germany). Breast cancer cells transduced with control
vector (MDA-MB-231-pcDNA3) or with cDNA for the breast
cancer resistance protein BCRP (MDA-MB-231-BCRP clone 23)
were maintained under standard conditions as described above for
CCRF-CEM cells. The generation of the cell lines followed a
published protocol [31]. The cell lines were continuously
maintained in 800 ng/ml gentamicin (Invitrogen, Karlsruhe,
Germany). Oxidative stress-related cell lines: The mouse thymic
lymphoma-derived WEHI7.2 parental cell line was obtained from
Dr. Roger Miesfeld (University of Arizona, Tucson, AZ). Cells
were maintained in Dulbecco’s Modified Eagle Medium - low
glucose (Invitrogen, Carlsbad, CA) supplemented with 10 % calf
serum (Hyclone Laboratories, Logan, UT) at 37uCi na5%C O 2
humidified environment. Stock cultures were maintained in
exponential growth at a density between 0.02 and 2610
6 cells/
ml. WEHI7.2 cells stably transfected with and overexpressing
human bcl-2 (Hb12), constructed and maintained as described in
[32], were also obtained from Dr. Miesfeld. Thioredoxin
overexpressing cells (THX) were constructed by stably transfecting
human thioredoxin into WEHI7.2 cells, then selecting and
maintaining clones as described [33]. THX cells express 1.8-fold
more thioredoxin than the parental cells [33]. Catalase overex-
pressing cells were constructed by stably transfecting WEHI7.2
cells with a vector containing rat catalase as described [34]. The
CAT38 clone expressing 1.4-fold parental cell catalase activity was
selected and maintained in 800 mg/ml G418 (GIBCO-BRL).
Hydrogen peroxide resistant cells (200R) were developed by
subculturing parental cells in the presence of fresh H2O2 every
three days as described [35]. This procedure resulted in a
population of cells that is 2.8-fold more resistant to 200 mMH 2O2
than the parental cells. 200R cells were maintained in the presence
of 200 mMH 2O2. Any variant normally grown in the presence of
drug was cultured in the absence of drug for one week prior to
each experiment.
Drug Response
The sulforhodamine B assay for the determination of drug
sensitivity in the NCI cell lines has been reported [36]. The
inhibition concentration 50% (IC50) values for free and formulated
arsenic trioxide (Trisenox) as well as for other arsenic compounds
(potassium arsenite, dihydro-1,3,2-dithioarsenol-2-ylmercapto-
acetic acid) and standard cytostatic drugs have been deposited in
the database of the Developmental Therapeutics Program of the
NCI (http://dtp.nci.nih.gov). Their chemical structures are shown
in Figure 1.
Growth Inhibition Assay: The in vitro response to drugs was
evaluated by means of a growth inhibition assay as described [37].
Aliquots of 5610
4 cells/ml were seeded in 24-well plates and drugs
Figure 1. Chemical structures of arsenic trioxide, potassium
arsenite, and dihydro-1,3,2-dithiarsenol-2ylmercapto-acetic
acid.
doi:10.1371/journal.pone.0035584.g001
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trioxide was used in different doses to allow calculation of IC50
values. Cells were counted 7 days after treatment with the drugs.
The resulting growth data represent the net outcome of cell
proliferation and cell death.
MTS assay: The response of WEHI7.2 parental cells and
WEHI7.2 cell variants towards arsenic trioxide was measured
using the MTS assay (Promega Corp., Madison, WI, USA) as
described previously [38]. Briefly, cells were plated at 1.5610
4
cells/well in 100 ml medium in a 96-well plate and incubated in
the absence or presence of the indicated concentrations of arsenic
trioxide for 48 hrs. Relative absorbance was measured by
incubating the cells for 3 hrs at 37uC with the MTS solution,
prepared and used according to the manufacturer’s protocol
(Promega Corp., Madison, WI), and reading at 490 nm using a
Microplate Autoreader (Bio-Tek Instruments, Winooski, VT).
Response was calculated as percent absorbance of untreated
control. The IC50 represent the mean of three independent
experiments. The degrees of resistance were calculated by dividing
the IC50 of transfected cell lines and multidrug-resistant cell lines,
respectively, by the IC50 value of their corresponding mock vector
control or parental cell line.
Microarray-Based Bioinformatic and Statistical Analyses
Cell lines of the NCI-60 panel were grown under standard
conditions [29]. RNA isolation and microarray hybridization
procedures have been described [39–40]. The microarray data
have been deposited at the website of the NCI Developmental
Therapeutics Program (http://dtp.nci.nih.gov). Hierarchical clus-
ter analysis is an explorative statistical method and aims to group
at first sight heterogeneous objects into clusters of homogeneous
objects. Objects are classified by calculation of distances according
to the closeness of between-individual distances. All objects are
assembled into a cluster tree (dendrogram). The merging of objects
with similar features leads to the formation of a cluster, where the
length of the branch indicates the degree of relatedness. The
procedure continues to aggregate clusters until there is only one.
The distance of a subordinate cluster to a superior cluster
represents a criterion for the closeness of clusters as well as for the
affiliation of single objects to clusters. Thus, objects with tightly
related features appear together, while the separation in the cluster
tree increases with progressive dissimilarity. Previously, cluster
models have been validated for gene expression profiling and for
approaching molecular pharmacology of cancer [39,41]. Cluster
analyses applying the WARD method were done by means of the
WinSTAT program (Kalmia Co., Cambridge, USA). Missing
values are automatically omitted by the program and the closeness
of two joined objects is calculated by the number of data points
they contained. In order to calculate distances of all variables
included in the analysis, the program automatically standardizes
the variables by transforming the data with a mean=0 and a
variance=1. To visualize the relationships between the IC50
values for arsenic trioxide and mRNA expression levels by cluster
analyses, cluster image maps were formed.
For COMPARE analysis, the mRNA expression values of genes
of interest and IC50 values for free and formulated arsenic trioxide
(Trisenox) of the NCI cell lines were selected from the NCI
database (http://dtp.nci.nih.gov). The mRNA expression has been
determined by microarray analyses as reported [39]. COMPARE
analyses were performed to produce rank-ordered lists of genes
expressed in the NCI cell lines. The methodology has been
described previously in detail [42]. Briefly, every gene of the NCI
microarray database was ranked for similarity of its mRNA
expression to the IC50 values for the corresponding compound. To
derive COMPARE rankings, a scale index of correlations
coefficients (R-values) was created. In the standard COMPARE
approach, greater mRNA expression in cell lines correlate with
enhanced drug resistance, whereas in reverse COMPARE analyses
greater mRNA expression in cell lines indicated drug sensitivity.
The Ingenuity Pathway Analysis software (IPA) (Ingenuity
Systems, Mountain View, CA, USA; http://www.ingenuity.com)
was utilized to identify networks and pathways of interacting genes
and other functional groups in genomic data. Using the IPA
Functional Analysis tool we were able to associate biological
functions and diseases to the experimental results. Moreover, we
used a biomarker filter tool and the Network Explorer for
visualizing molecular relationships.
Pearson’s correlation test was used to calculate significance
values and rank correlation coefficients as a relative measure for
the linear dependency of two variables. This test was implemented
into the WinSTAT Program (Kalmia Co.). Pearson’s correlation
test determined the correlation of rank positions of values. Ordinal
or metric scaling of data is suited for the test and transformed into
rank positions. There is no condition regarding normal distribu-
tion of the data set for the performance of this test. We used
Pearson’s correlation test to correlate microarray-based mRNA
expression of candidate genes with the IC50 values for arsenic
trioxide.
The Chi
2-test was applied to bivariate frequency distributions of
pairs of nominal scaled variables. It was used to calculate
significance values (P-values) and rank correlation coefficients (R-
values) as a relative measure for the linear dependency of two
variables. This test was implemented into the WinSTAT program
(Kalmia Co.). The Chi
2-test determines the difference between
each observed and theoretical frequency for each possible
outcome, squaring them, dividing each by the theoretical
frequency, and taking the sum of the results. Performing the
Chi
2-test necessitated defining cell lines as being sensitive or
resistant to arsenic trioxide. This was done by taking the median
IC50 value (log10=25.346 M for formulated arsenic trioxide and
log10=25.467 M for free arsenic trioxide) as a cut-off threshold.
Results
Cross-resistance of Arsenic Compounds in the NCI Cell
Line Panel
The NCI database contained 9 arsenic-containing compounds,
of which five were inactive or only minimally active against the
cancer cell lines tested. The four cytotoxic arsenicals were free and
formulated arsenic trioxide as well as potassium arsenite, dihydro-
1,3,2-dithioarsenol-2-ylmercapto-acetic acid. The inactive or
weakly active arsenicals were arsenic(III) 2,3-dimercapto succinic
acid, simethyl arsinic acid, lithiume arsenate (Li3AsO4), sodium
arsenic tungsten polyoxymetalate hydrate, and arsenic acid
(H3AsO4) trilithium salt. These substances have been investigated
over a dose range from 10
28 to 10
24 M in 60 tumor cell lines and
IC50 values have been calculated thereof. The IC50 values for the
four cytotoxic arsenic compounds are shown in Figure 2. Free
and formulated arsenic trioxides were more cytotoxic than the two
other arsenicals. Leukemia cell lines were more sensitive than cell
lines from other tumor types. Among cell lines of solid cancers, cell
lines from brain tumors, melanoma, or breast cancer were most
sensitive to free or formulated arsenic trioxide, whereas colon or
prostate cancer cell lines were most resistant. Cell lines from lung
or kidney cancer showed intermediate sensitivity.
We correlated the IC50 values for free and formulated arsenic
trioxide with those of other arsenic-containing compounds
(potassium arsenite, dihydro-1,3,2-dithioarsenol-2-ylmercapto-
As2O3 Resistance of Tumor Cells
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formulated arsenic trioxide were highly correlated
(P=4.14610
214). Furthermore, the IC50 values for arsenic
trioxide of the cell line panel were significantly correlated with
the IC50 values for potassium arsenite and dihydro-1,3,2-
dithiarsenol-2-ylmercapto-acetic acid, indicating that the cell lines
reveal cross-resistance to arsenic-containing drugs.
Gene-hunting Approach
COMPARE and Cluster Analyses of Microarray-Based
mRNA Hybridization. We applied a pharmacogenomic ap-
proach to explore novel molecular determinants of sensitivity and
resistance to arsenic trioxide. We mined the genome-wide mRNA
expression database of the NCI and correlated the expression data
with the IC50 values for arsenic trioxide. This represents a
hypothesis-generating bioinformatic approach, which allows the
identification of novel putative molecular determinants of cellular
response towards arsenic trioxide.
Standard COMPARE analysis was performed to identify genes,
while expression was associated with arsenic trioxide resistance.
Vice versa, reverse COMPARE analysis was done to find factors
associated with arsenic trioxide sensitivity. Only correlations with a
correlation coefficient of R.0.5 (standard COMPARE) or
R,20.55 (reverse COMPARE) were considered (Table S1).
Among the genes identified by this approach were genes from
diverse functional groups such as signal transduction (SYDE1, SFN,
PPAP2C, EZR, GPRC5A), DNA biosynthesis and transcriptional
regulation (UPRT, MED12, SFRS15), adhesion and cytoskeletal
organization (PDLIM5, PERP, DSG2, SDC1) and others (ID1,
ILKAP, HMIX2, UBA1, ARHGEF6, CYTH1, TXNRD1, CMTM4).
Next, the genes identified by standard and reverse COMPARE
analyses were subjected to hierarchical cluster analysis. The
dendrogram obtained by this procedure can be divided into three
major branches (Figure 3). The distribution of cell lines being
sensitive or resistant to formulated arsenic trioxide was signifi-
cantly different between the branches of the dendrograms. The
sensitive/resistant ratio in cluster 1 was 2:20, 22:10 in cluster 2 and
6:0 in cluster 3. The distribution of cell lines among the
dendrogram predicted resistance to formulated arsenic trioxide
with significance (P=3.2610
26; Chic
2-test; Table 2). A similar
relationship was found for free arsenic trioxide (P=4.5610–6;
Chic
2-test; Table 2).
Figure 2. IC50 values of four arsenicals for the NCI cell line panel. Mean values and SEM of IC50 are grouped according to the tumor
origin of the cell lines.
doi:10.1371/journal.pone.0035584.g002
Table 1. Cross-resistance between arsenic trioxide and other arsenic compounds in the NCI cell line panel.
free As2O3 formulated As2O3
formulated As2O3 4.14610
214* N/A
potassium arsenite (KAsO2) 1.76610
212* 2.51610
29*
dihydro-1,3,2-dithiarsenol-2-ylmercapto-acetic acid 0.04565* n.s.
Log10 IC50 values obtained from SRB assays have been subjected to Pearson’s correlation test.
N/A, not applicable; N.S. not significant (P.0.05). * denotes significant correlation.
doi:10.1371/journal.pone.0035584.t001
As2O3 Resistance of Tumor Cells
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As a next step, we employed a signaling pathway analysis to
better understand the biological consequences of arsenic trioxide
treatment. The genes identified by microarray and COMPARE
analyses were subjected to Ingenuity Pathway Analysis (version
6.5). The genes identified by COMPARE analysis have a function
in cellular development, hair and skin development and function,
cell cycle, cell death, and cell morphology and others (Figure 4A).
The top canonical pathways were signaling routes for p53, ILK,
and actin cytoskeleton (Figure 4B).
Candidate Gene Approach
In the second part of our investigation, we analyzed whether
classical mechanisms of resistance towards established anti-cancer
Figure 3. Hierarchical cluster analysis of microarray-based mRNA gene expression obtained by standard and reverse COMPARE
analyses. The dendrogram shows the clustering of the NCI-60 cell line panel and indicates the degrees of relatedness between cell lines.
doi:10.1371/journal.pone.0035584.g003
Table 2. Separation of clusters of the NCI cell line panel obtained by the hierarchical cluster analysis shown in Figure 3 in
comparison to drug sensitivity.
Partition
a Cluster 1 Cluster 2 Cluster 3 Chi
2 Test
formulated arsenic trioxide sensitive #25.346 2 22 6
resistant .25.346 20 10 0 3.32635610
26
free arsenic trioxide sensitive #25.467 2 21 6
resistant .25.467 20 10 0 4.50505610
26
aThe median log10IC50 value (M) for each drug was used as a cut-off to separate tumor cell lines as being "sensitive" or "resistant".
doi:10.1371/journal.pone.0035584.t002
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trioxide.
Role of oxidative stress response, damage, or metabolism
for resistance to arsenic trioxide. Figure 5 shows the arsenic
trioxide response of WEHI7.2 mouse thymic lymphoma cells
selected for resistance to H2O2 or stably transfected with catalase,
thioredoxin, or bcl-2. The CAT38 clone was 1.94-fold more
resistant to arsenic trioxide than the parental WEHI7.2 cells
(Figure 5A). Thioredoxin-transfected cells were 2.36-fold more
resistant to arsenic trioxide than WEHI7.2 cells (Figure 5B).
WEHI7.2 cells selected for resistance to H2O2 were not resistant to
arsenic trioxide (data not shown). Finally, bcl-2-transfected cells
were 1.86-fold more resistant to arsenic trioxide than WEHI7.2
cells (Figure 5C).
Role of ABC-Transporters for Resistance to Arsenic
Trioxide. As multidrug resistance (MDR) and MDR-conferring
drug transporters of the ABC transporter family are a major cause
of failure to many established anti-cancer drugs, we addressed the
question, whether cellular response to arsenic trioxide treatment
may also be affected by ABC transporters. The role of three ABC
transporters has been exemplarily validated using cell lines that
selectively overexpress either the ABCB1 (MDR1), ABCC1 (MRP1),
or the ABCG2 (BCRP) gene. Based on the IC50 values calculated
from the dose response curves shown in Figure 6A, ABCB1
(MDR1)-overexpressing CEM/ADR5000 cells were slightly more
Figure 4. Identification of signaling pathways and interaction of gene products associated with cellular response of cancer cells
towards formulated arsenic trioxide. The genes identified by COMPARE analyses (Table S1) were subjected to Ingenuity Pathway Analysis
Software. (A) Top 10 categories of biological functions of the candidate genes. (B) Top 10 canonical signaling pathways, which the candidate genes
were assigned to.
doi:10.1371/journal.pone.0035584.g004
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cells (degree of increased sensitivity: 0.69). ABCC1(MRP1)-overex-
pressing HL60/AR cells and ABCG2 (BCRP)-overexpressing
MDA-MB-231-BCRP cells were not more resistance to arsenic
trioxide than their drug-sensitive counterparts (Figure 6B and
C).
Discussion
Gene-hunting Approach
In the present investigation, we analyzed molecular determi-
nants of sensitivity and resistance of cancer tumor cell lines
towards arsenic trioxide. In general, there are two ways to reach
this goal: (1) gene-hunting and (2) candidate gene approaches.
Applying the first approach, we correlated the IC50 values for
arsenic trioxide of 60 tumor cell lines with the microarray-based
transcriptome-wide mRNA expression levels of this cell line panel
[39] by COMPARE analysis. This approach has been successfully
used to unravel the mode of action of novel compounds [43].
Cluster and COMPARE analyses are also useful for comparing
gene expression profiles with IC50 values for investigational drugs
to identify candidate genes for drug resistance [44] and to identify
prognostic expression profiles in clinical oncology [45].
We identified genes from diverse functional groups, which were
tightly associated with the response of tumor cells to arsenic
trioxide, such as genes belonging to p53 signaling and others, most
of which have not been associated with cellular response to arsenic
trioxide. Interestingly, the oxidative stress response and DNA
repair (TXNRD1 and UBA1) appeared in the COMPARE analysis,
which speaks DNA damage as mode of action of arsenic trioxide.
The gene-hunting approach applied by us delivered several novel
candidate genes that may regulate the response of cancer cells to
arsenic trioxide. These results merit further investigation to prove
the contribution of these genes to arsenic trioxide resistance.
The microarray technology has also been applied by other
investigators to analyze genes potentially relevant for cellular
response towards arsenic trioxide [46–49]. In these studies, the
Figure 5. Cytotoxicity of arsenic trioxide on WEHI7.2 cell lines.
Cells stably transfected with expression vectors carrying cDNAs for (A)
catalase, (B) thioredoxin, or (C) Bcl-2, and with mock control vector.
Values represent the mean (6 SEM) of three independent experiments.
doi:10.1371/journal.pone.0035584.g005
Figure 6. Cytotoxicity of sensitive and multidrug-resistant
tumor cells to arsenic trioxide. (A) Sensitive CCRF-CEM and
multidrug-resistant ABCB1 (MDR1)-overexpressing CEM/ADR5000 cells;
(B) sensitive HL60 and multidrug-resistant ABCC1 (MRP1)-overexpressing
HL60/AR cells; and (C) sensitive MDA-MB-231-pcDNA and multidrug-
resistant ABCG2 (BCRP)-transduced MDA-MB-231-BCRP cells. Values
represent the mean (6 SEM) of three independent experiments.
doi:10.1371/journal.pone.0035584.g006
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cell lines has been compared to identify genes up- or down-
regulated upon drug challenge. This approach delivers genes as a
response to cytotoxic stress and is different from our approach. In
the present investigation, we correlated the basal gene expression
of untreated cells in a panel of 60 cell lines with their IC50 values to
arsenic trioxide. These two experimental settings refer to two
different types of drug resistance. The first approach may unravel
genes conferring resistance after drug treatment. This type is called
acquired or secondary resistance. In our approach, we identify
genes involved in the initial responsiveness of tumor cells to drug
treatment. This type is known as inherent or primary resistance.
Both types of drug resistance can clinically be observed. As an
example, small cell lung cancer frequently responds well to
chemotherapy at the beginning of a therapy, but gradually
develops resistance during subsequent treatment courses (acquired
or secondary resistance). Non-small cell lung cancers do not
respond well to chemotherapy even at the beginning of a
treatment (inherent or primary resistance). This implies that those
tumors express drug resistance mechanisms prior to drug
treatment.
It is interesting to note that the microarray analysis in the
current study identified genes from functional groups similar to
those that previous studies identified as associated with cellular
response to arsenic trioxide. These include cell cycle-regulating
genes [46249], transcription factors and cofactors [47,49], signal
transducers [46,50], DNA repair genes [46,49] and apoptosis-
regulating genes [47]. This indicates that these cellular functions
may be of importance for resistance to arsenic trioxide. The
appearance of these genes was a clue for the involvement of
reactive oxygen species (see above), which was indeed validated by
our subsequent experiments. Liu et al. [51] also identified
oxidative stress response genes and proteins related to the NRF2
pathway in the NCI-60 cell line panel as possible determinants of
response to arsenic trioxide. In our approach, we analyzed not the
entire set of significantly correlating genes as Liu and colleagues
did, but only the genes with the highest COMPARE ranks. Here,
genes related to p53 signaling, cell cycle arrest, DNA repair, and
apoptosis provide clues on reactive oxygen species as underlying
mechanism. Therefore, the report of Liu et al. and the present
investigation do nicely complement each other and strengthen the
hypothesis of oxidative stress response as important mechanism for
arsenic trioxide’s response in cancer cells.
Additional functional groups of genes, which did not appear in
the present investigation, were proteasome degradation, RNA
processing calcium signaling, the IFN pathway and protein
synthesis [47,50]. Other arsenic trioxide effects include impair-
ment of the genomic differentiation program in human macro-
phages [52] and alterations in the expression of multiple micro-
RNAs. A more detailed analysis is required to determine the
relative importance of the multiple effects in the observed drug
response.
Candidate Gene Approach
As a second approach, we analyzed whether several classical
drug resistance mechanisms may also play a role for the resistance
towards arsenic trioxide. These classical mechanisms did not
appear in our COMPARE analyses, although their mRNA
expression values were also included into the analysis. This
indicates that the above genes identified by COMPARE might be
more relevant for response of tumor cells towards arsenic trioxide.
Nevertheless, the role of those classical drug resistance mecha-
nisms is worth investigating, because of their generally accepted
role for drug resistance to anti-cancer agents.
It has been demonstrated that arsenic trioxide generates ROS
(preferentially H2O2 but also O2
N- [22–24,53]) and that the
cytotoxic activity of arsenic trioxide is reduced by N-acetylcysteine
[27,54–56] and enhanced by buthionine sulfoximine [54,57,58].
These results imply that oxidative stress induced by arsenic
trioxide is important for cytotoxicity. Therefore, it is surprising
that contradictory results have been reported for ROS-detoxifying
enzymes. Either increased, decreased, or unchanged enzymatic
activities upon cellular challenge with arsenic trioxide have been
observed for glutathione S-transferase-pi [25,26,58], glutathione
peroxidase [25,59–61], glutathione reductase [25,60], catalase
[27,55,60,62,63], superoxide dismutases [25,27,56,61] and thior-
edoxin reductase [64]. To clarify the role of ROS-detoxifying
enzymes, it may not be sufficient to measure enzymatic activities.
Therefore, we have used cell lines transfected with cDNAs for
catalase or thioredoxin and treated them with arsenic trioxide. We
found that transfection of catalase cDNA or thioredoxin cDNA
conferred resistance towards arsenic trioxide. In addition to the
glutathione redox system, the thioredoxin system represents
another major antioxidant system maintaining the intracellular
redox state. Thioredoxin scavenges ROS, regulates antioxidant
enzymes, and inhibits proapoptotic proteins [65]. Oxidized
thioredoxin is reduced by thioredoxin reductase, which is relevant
for arsenic trioxide’s activity as shown in the present investigation.
It is unclear from the literature, whether arsenic trioxide induces
apoptosis and whether Bcl-2 is protective. This is further
complicated by the conflicting data indicating that arsenic trioxide
can up- and down-regulate the apoptosis-regulating bcl-2, bcl-xL,
and bax genes depending on the model system [18,66–68].
Therefore, we attempted to clarify the role of the anti-apoptotic
bcl-2 gene by treating bcl-2 transfected cells with arsenic trioxide.
As expected, we observed that bcl-2 mediated resistance to this
compound providing evidence for the importance of the
mitochondrial pathway of apoptosis for arsenic trioxide’s cytotox-
icity towards cancer cells.
ABC Transporters and Multidrug Resistance
Multidrug resistance (MDR) is based on numerous mechanisms,
one of which is the influence of ATP-binding cassette (ABC)
transporters. They are involved in the active transport of
phospholipids, ions, peptides, steroids, polysaccharides, amino
acids, bile acids, pharmaceutical drugs and other xenobiotic
compounds [16]. ABCB1 (P-glycoprotein, P-gp, MDR1), ABCC1-
C6 (MRP1-6) and ABCG2 (BCRP) confer resistance to cytostatic
drugs of tumors and contribute to the failure of tumor [17]. It is
still unclear, to which extent human ABC transporters contribute
to arsenic trioxide-related drug resistance phenomena.
While some authors found no cross-resistance or even collateral
sensitivity of cell lines overexpressing P-glycoprotein (MDR1,
ABCB1) [18,69–71] or MRP1 (ABCC1) [18,20,21,72,73], others
claim a role of these ABC transporters in arsenic trioxide
resistance [19,74]. This discussion, i.e. whether arsenic trioxide
leads to an induction or repression of these two drug transporters,
is controversial [66,70,75–80]. The role of BCRP (ABCG2),
another important multidrug resistance-conferring ABC-trans-
porter has not been addressed as yet. For this reason, we have
analyzed multidrug-resistant CBM/ADR5000 cells which specif-
ically overexpress P-glycoprotein, but none of the other ABC
transporters [17,30]. These cells were slightly more sensitive to
arsenic trioxide, indicating that P-glycoprotein does not play a
major role for resistance to this drug. Furthermore, we have
analyzed HL60/AR cells, which have been reported to overex-
press MRP1 [81]. In a previous investigation we found that other
transporters [82] are also overexpressed in this cell line. Since this
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conclude that these ABC transporters are not relevant for
resistance towards this drug. Likewise, MDA-MB-231/BCRP
cells transfected with a cDNA for BCRP were not cross-resistant to
arsenic trioxide. In summary, our data do not support that the
ABC-transporters P-gp, MRP1 and BCRP considerably contrib-
ute to resistance to arsenic trioxide. This indicates that clinically
refractory tumors overexpressing these ABC transporters might
still be responsive to arsenic trioxide.
Conclusions
In the present investigation, we analyzed molecular determi-
nants of sensitivity and resistance of cancer tumor cell lines to
arsenic trioxide. By the gene-hunting approach, we identified
genes, which were not yet known to be linked to responsiveness of
cancer cells towards arsenic trioxide-. These genes need to be
investigated in more detail in future studies. By the candidate gene
approach, we analyzed the role of several classical drug resistance
mechanisms for the resistance towards arsenic trioxide-apoptotic
bcl-2 gene as well as the thioredoxin reductase gene. ABC
transporters were not responsible for resistance to arsenic trioxide
(MRP1, BCRP).
Our approach clearly revealed that response of tumor cells
towards arsenic trioxide is multi-factorial. At least some of the
functional groups of genes are also implicated in clinical
responsiveness of tumors towards chemotherapy. Whether the
genes identified in the present study also determine clinical
responsiveness to arsenic trioxide merits further investigation.
Supporting Information
Table S1 Genes determining sensitivity or resistance
towards formulated arsenic trioxide in the NCI cell line
panel as identified by microarray mRNA expression
profiling and COMPARE analysis (see Supporting
Information).
(DOC)
Author Contributions
Conceived and designed the experiments: TE. Performed the experiments:
MT MMB JB KH. Analyzed the data: SS. Wrote the paper: TE PKP SS.
References
1. Miller WH Jr., Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms
of action of arsenic trioxide. Cancer Res 62: 3893–3903.
2. Klaassen CD (1996) Heavy metals and heavy-metal antagonists. In: J.G.
Hardman, AG Gilman, and LE Limbird (eds.) Goodman and Gilman’s The
Pharmacological basis of therapeutics, 1649–1672. New York: McGraW-HILL.
3. Haller JS (1975) Therapeutic mule: the use of arsenic in the nineteenth century
materia medica. Pharmacy in History 17: 87–100.
4. Chan PC, Huff J (1997) Arsenic carcinogenesis in animals and in humans:
mechanistic, experimental, and epidemiological evidence. J Environ Sci Health
Part C Environ Carcinog Ecotoxicol Rev C15: 83–122.
5. Knowles PC, Benson AA (1983) The biogeochemistry of arsenic. Trends
Biochem Sci 8: 178–180.
6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. (1997) Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II.
Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:
3354–3360.
7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, et al. (2001)
United States multicenter study of arsenic trioxide in relapsed acute
promyelocytic leukemia. J Clin Oncol 19: 3852–3860.
8. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, et al. (1996) In vitro studies on
cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment
of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with
downregulation of Bcl-2 expression and modulation of PML-RARa/PML
proteins. Blood 88: 1052–1061.
9. Huang XJ, Wiernik PH, Klein RS, Gallagher RE (1999) Arsenic trioxide
induces apoptosis of myeloid leukemia cells by activation of caspases. Med
Oncol 16: 58–64.
10. Anderson KC, Boise LH, Louie R, Waxman S (2002) Arsenic trioxide in
multiple myeloma: rationale and future directions. Cancer J 8: 12–25.
11. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, et al.
(2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the
bone marrow microenvironment. Mol Cancer Ther 1: 851–860.
12. Liu Q, Hilsenbeck S, Gazitt Y (2003) Arsenic trioxide-induced apoptosis in
myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of
caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101:
4078–4087.
13. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, et al. (2000) Arsenic trioxide
induces dose- and time-dependent apoptosis of endothelium and may exert an
antileukemic effect via inhibition of angiogenesis. Blood 96: 1525–1530.
14. Sawyers CL (2001) Research on resistance to cancer drug Gleevec. Science
294(5548): 1834.
15. Efferth T, Kaina B (2004) Microarray-based prediction of cytotoxicity of tumor
cells to arsenic trioxide. Cancer Genomics Proteomics 1: 363–370.
16. Efferth T (2001) The human ATP-binding cassette transporter genes: from the
bench to the bedside. Curr Mol Med 1: 45–65.
17. Gillet JP, Efferth T, Remacle J (2007) Chemotherapy-induced resistance by
ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237–262.
18. Perkins C, Kim CN, Fang G, Bhalla KN (2000) Arsenic induces apoptosis of
multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or
overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 95: 1014–1022.
19. Chen X, Zhang M, Liu LX (2009) The overexpression of multidrug resistance-
associated proteins and gankyrin contribute to arsenic trioxide resistance in liver
and gastric cancer cells. Oncol Rep 22: 73–80.
20. Seo T, Urasaki Y, Takemura H, Ueda T (2005) Arsenic trioxide circumvents
multidrug resistance based on different mechanisms in human leukemia cell
lines. Anticancer Res 25: 991–998.
21. Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, et al. (2008) A novel
arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-
overexpressing cell lines. Leukemia 22: 1853–1863. Erratum in: Leukemia 23:
431.
22. Brown E, Yedjou CG, Tchounwou PB (2008) Cytotoxicity and oxidative stress
in human liver carcinoma cells exposed to arsenic trioxide (HepG(2). Met Ions
Biol Med 10: 583–587.
23. Bowling BD, Doudican N, Manga P, Orlow SJ (2008) Inhibition of
mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide
cytotoxicity via a reactive oxygen species dependent mechanism. Cancer
Chemother Pharmacol 63: 37–43.
24. Laparra JM, Ve ´lez D, Barbera ´ R, Farre ´ R, Montoro R (2008) As2O3-induced
oxidative stress and cycle progression in a human intestinal epithelial cell line
(Caco-2). Toxicol In Vitro 22: 444–449.
25. Yeh JY, Cheng LC, Ou BR, Whanger DP, Chang LW (2002) Differential
influences of various arsenic compounds on glutathione redox status and
antioxidative enzymes in porcine endothelial cells. Cell Mol Life Sci 59:
1972–1982.
26. Wang X, Kong L, Zhao J, Yang P (2002) Arsenic trioxide in the mechanism of
drug resistance reversal in MCF-7/ADM cell line of human breast cancer.
Zhonghua Zhong Liu Za Zhi 24: 339–343.
27. Han YH, Kim SH, Kim SZ, Park WH (2008) Apoptosis in arsenic trioxide-
treated Calu-6 lung cells is correlated with the depletion of GSH levels rather
than the changes of ROS levels. J Cell Biochem 104: 862–878.
28. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, et al. (1988)
Feasibility of drug screening with panels of human tumor cell lines using a
microculture tetrazolium assay. Cancer Res 48: 589 –601.
29. Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, et al. (1990)
Susceptibility of multidrug-resistant human leukemia cell lines to human
interleukin 2-activated killer cells. Cancer Res 50: 6793–6799.
30. Bru ¨gger D, Herbart H, Gekeler V, Seitz G, Liu C, et al. (1999) Functional
analysis of P-glycoprotein and multiderug resistance-associated protein-ralated
multidrug resistance in AML-blasts. Leuk Res 23: 467–475.
31. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A
multidrug resistance transporter from human MCF-7 breast cancer cells. Proc
Natl Acad Sci USA 95: 15665–15670.
32. Lam M, Dubyak G, Chen L, Nunez G, Miesfeld RL, et al. (1994) Evidence that
BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+
fluxes. Proc Natl Acad Sci USA 91: 6569–6573.
33. Baker A, Payne CM, Briehl MM, Powis G (1997) Thioredoxin, a gene found
overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer
Res 57: 5162–5167.
34. Tome ME, Baker AF, Powis G, Payne CM, Briehl MM (2001) Catalase-
overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and
exhibit increased net tumor growth. Cancer Res 61: 2766–2773.
35. Tome ME, Briehl MM (2001) Thymocytes selected for resistance to hydrogen
peroxide show altered antioxidant enzyme profiles and resistance to dexameth-
asone-induced apoptosis. Cell Death Differ 8: 953–961.
36. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, et al. (1990)
Comparison of in vitro anticancer-drug-screening data generated with a
As2O3 Resistance of Tumor Cells
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e35584tetrazolium assay versus a protein assay against a diverse panel of human tumor
cell lines. J Natl Cancer Inst 82: 1113–1118.
37. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, et al. (2003) Molecular
modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382–394.
38. Efferth T, Briehl MM, Tome ME (2003) Role of antioxidant genes for the
activity of artesunate against tumor cells. Int J Oncol 23: 1231–1235.
39. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene
expression database for the molecular pharmacology of cancer. Nat Genet 24:
236–244.
40. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, et al. (2008)
Integrating global gene expression and radiation survival parameters across the
60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer
Res 68: 415–424.
41. Efferth T, Fabry U, Osieka R (1997) Apoptosis and resistance to daunorubicin in
human leukemic cells. Leukemia 11: 1180–1186.
42. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, et al. (1997)
Identification of epidermal growth factor receptor and erbB2 pathway inhibitors
by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505–1515.
43. Leteurtre F, Kohlhagen G, Paull KD, Pommier Y (1994) Topoisomerase II
inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941
(Losoxantrone) in the National Cancer Institute preclinical antitumor drug
discovery screen. J Natl Cancer Inst 86: 1239–1244.
44. Efferth T, Gebhart E, Ross DD, Sauerbrey A (2003) Identification of gene
expression profiles predicting tumor cell response to l-alanosine. Biochem
Pharmacol 66: 613–621.
45. Efferth T, Olbrich A, Bauer R (2002) mRNA expression profiles for the response
of human tumor cell lines to the antimalarial drugs artesunate, arteether, and
artemether. Biochem Pharmacol 64: 617–623.
46. Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, et al. (2004) Comparison of
effects of As2O3 and As4O6 on cell growth inhibition and gene expression
profiles by cDNA microarray analysis in SiHa cells. Oncol Rep 12: 573–580.
47. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, et al. (2005) Systems
analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced
cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad
Sci U S A 102: 7653–7658.
48. Zhao S, Zhang J, Zhang X, Dong X, Sun X (2008) Arsenic trioxide induces
different gene expression profiles of genes related to growth and apoptosis in
glioma cells dependent on the p53 status. Mol Biol Rep 35: 421–429.
49. Burnichon V, Jean S, Bellon L, Maraninchi M, Bideau C, et al. (2003) Patterns
of gene expressions induced by arsenic trioxide in cultured human fibroblasts.
Toxicol Lett 143: 155–162.
50. Wang HY, Liu SX, Zhang M (2003) Gene expression profile changes in NB4
cells induced by arsenic trioxide. Acta Pharmacol Sin 24: 646–650.
51. Liu Q, Zhang H, Smeester L, Zou F, Kesic M, et al. (2010) The NRF2-mediated
oxidative stress response pathway is associated with tumor cell resistance to
arsenic trioxide across the NCI-60 panel. BMC Med Genomics 3: 37.
52. Bourdonnay E, Morzadec C, Sparfel L, Galibert MD, Jouneau S, et al. (2009)
Global effects of inorganic arsenic on gene expression profile in human
macrophages. Mol Immunol 46: 649–656.
53. Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, et al. (2002) Arsenic trioxide
induces apoptosis through a reactive oxygen species-dependent pathway and loss
of mitochondrial membrane potential in HeLa cells. Int J Oncol 21: 57–63.
54. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, et al. (2002) Arsenic
trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell
lines. Life Sci 70: 2253–2269.
55. Biswas S, Zhao X, Mone AP, Mo X, Vargo M, et al. (2010) Arsenic trioxide and
ascorbic acid demonstrate promising activity against primary human CLL cells
in vitro. Leuk Res 34: 925–931.
56. Han YH, Kim SZ, Kim SH, Park WH (2008) Suppression of arsenic trioxide-
induced apoptosis in HeLa cells by N-acetylcysteine. Mol Cells 26: 18–25.
57. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y, Gordon LI (2002) Arsenic
trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines:
enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer
Res 8: 566–572.
58. Yang CH, Kuo ML, Chen JC, Chen YC (1999) Arsenic trioxide sensitivity is
associated with low level of glutathione in cancer cells. Br J Cancer 81: 796–799.
59. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S (1999) Arsenic
trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a
hydrogen peroxide-dependent pathway. Blood 94: 2102–2111.
60. Allen T, Rana SV (2004) Effect of arsenic (AsIII) on glutathione-dependent
enzymes in liver and kidney of the freshwater fish Channa punctatus. Biol Trace
Elem Res 100: 39–48.
61. Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, et al. (2006) Role of oxidative stress in
the apoptosis of hepatocellular carcinoma induced by combination of arsenic
trioxide and ascorbic acid. Acta Pharmacol Sin 27: 1078–1084.
62. Coe E, Schimmer AD (2008) Catalase activity and arsenic sensitivity in acute
leukemia. Leuk Lymphoma 49: 1976–1981.
63. Giommarelli C, Corti A, Supino R, Favini E, Paolicchi A, et al. (2009) Gamma-
glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells
and cellular sensitization by ascorbic acid. Free Radic Biol Med 46: 1516–1526.
64. Lu J, Chew EH, Holmgren A (2007) Targeting thioredoxin reductase is a basis
for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104:
12288–12293.
65. Tonissen KF, Di Trapani G (2009) Thioredoxin system inhibitors as mediators
of apoptosis for cancer therapy. Mol Nutr Food Res 53: 87–103.
66. Han B, Zhou G, Zhang Q, Zhang J, Wang X, et al. (2004) Effect of arsenic
trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis
of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol 4:
335–342.
67. Xue DB, Zhang WH, Yun XG, Song C, Zheng B, et al. (2007) Regulating
effects of arsenic trioxide on cell death pathways and inflammatory reactions of
pancreatic acinar cells in rats. Chin Med J (Engl) 120: 690–695.
68. Lee C, Lin Y, Huang M, Liu C, Chow J, et al. (2006) Increased cellular
glutathione and protection by bone marrow stromal cells account for the
resistance of non-acute promyelocytic leukemia acute myeloid leukemia cells to
arsenic trioxide in vivo. Leukemia Lymphoma 47: 521–529.
69. Chan JY, Siu KP, Fung KP (2006) Effect of arsenic trioxide on multidrug
resistant hepatocellular carcinoma cells. Cancer Lett 236: 250–258.
70. Wei H, Su H, Bai D, Zhao H, Ge J, et al. (2003) Arsenic trioxide inhibits p-
glycoprotein expression in multidrug-resistant human leukemia cells that
overexpress the MDR1 gene. Chin Med J (Engl) 116: 1644–1648.
71. Lehmann S, Bengtzen S, Paul A, Christensson B, Paul C (2001) Effects of arsenic
trioxide (As2O3) on leukemic cells from patients with non-M3 acute
myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of
resistance. Eur J Haematol 66: 357–364.
72. Salerno M, Petroutsa M, Garnier-Suillerot A (2002) The MRP1-mediated
effluxes of arsenic and antimony do not require arsenic-glutathione and
antimony-glutathione complex formation. J Bioenerg Biomembr 34: 135–145.
73. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A, et al. (2001) Resistance of
human multidrug resistance-associated protein 1-overexpressing lung tumor cells
to the anticancer drug arsenic trioxide. Biochem Pharmacol 61: 1387–1391.
74. Seo T, Urasaki Y, Ueda T (2007) Establishment of an arsenic trioxide-resistant
human leukemia cell line that shows multidrug resistance. Int J Hematol 85:
26–31.
75. Au WY, Chim CS, Wai Lie AK, Pang A, Kwong YL (2002) Real-time
quantification of the multidrug resistance-1 gene expression in relapsed acute
promyelocytic leukemia treated with arsenic trioxide. Haematologica. 87:
1109–1111.
76. Takeshita A, Shinjo K, Naito K, Matsui H, Shigeno K, et al. (2003) P-
glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are
induced by arsenic trioxide (As2O3), but are not the main mechanism of
As(2)O(3)-resistance in acute promyelocytic leukemia cells. Leukemia 17:
648–650.
77. Wang DH, Wei HL, Zhao HS, Hao CY, Min ZH, et al. (2005) Arsenic trioxide
overcomes apoptosis inhibition in K562/ADM cells by regulating vital
components in apoptotic pathway. Pharmacol Res 52: 376–385.
78. Wang T, Ma LM, Zhang HP, Wang HW, Yang LH, et al. (2007) The effect of
arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its
mechanisms. Zhonghua Xue Ye Xue Za Zhi 28: 438–443. [Article in Chinese].
79. Liang H, Zhang Y, Zhang JD, Gu J, Ma L, et al. (2007) Effects of arsenic
trioxide on expressions of vascular endothelial growth factor and P-glycoprotein
in multidrug resistant leukemia cell line K562/A02. Zhong Xi Yi Jie He Xue
Bao 5: 647–650. [Article in Chinese].
80. Xue YW, Han JG, Li BX, Yang BF (2007) [Reversal effect and mechanism of
arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901]
Yao Xue Xue Bao 42: 949–953. [Article in Chinese].
81. Efferth T, Davey M, Olbrich A, Ru ¨cker G, Gebhart E, et al. (2002) Activity of
drugs from traditional Chinese medicine toward sensitive and MDR1- or
MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells.
Blood Cells Mol Dis 28: 160–168.
82. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, et al. (2004)
Microarray-based detection of multidrug resistance in human tumor cells by
expression profiling of ATP-binding cassette transporter genes. Cancer Res 64:
8987–8993.
As2O3 Resistance of Tumor Cells
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e35584